The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Physician perceptions of testing practices in patients with EGFR mutated NSCLC
Jens Samol, MD, Tan Tock Seng Hospital & Faculty Appointment at Johns Hopkins University, Tan Tock Seng, Singapore, talks on the physicians’ perceptions of testing practices in patients with early or advanced stage EGFR-mutated NSCLC. A questionnaire was sent out to various physicians’ globally to explore the differences in testing for EGFR mutations in adenocarcinomas, concluding that practices differ widely based on the availability of testing for mutations. Testing was noted to increase from earlier to later stages. However, there is a possibility for patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) to be treated with adjuvant osimertinib, as investigated in the Phase III ADAURA (NCT02511106) trial. This interview took place during the virtual European Lung Cancer Congress 2022.
